Simvastatin enhances the radiosensitivity of p53‑deficient cells via inhibition of mouse double minute 2 homolog

Lee,Ji Young; Kim,Mi-Sook; Ju,Jae Eun; Lee,Mi So; Chung,Namhyun; Jeong,Youn Kyoung

doi:10.3892/ijo.2017.4192

Simvastatin enhances the radiosensitivity of p53‑deficient cells via inhibition of mouse double minute 2 homolog

Authors:
- Ji Young Lee
- Mi-Sook Kim
- Jae Eun Ju
- Mi So Lee
- Namhyun Chung
- Youn Kyoung Jeong
View Affiliations

Affiliations: Radiation Non-Clinical Center, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea, Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea, Department of Biosystems Engineering, College of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea
Published online on: November 6, 2017 https://doi.org/10.3892/ijo.2017.4192
Pages: 211-218

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Simvastatin exhibits anticancer activities, but its molecular mechanisms and radiosensitizing effects relative to p53 status remain unclear. In this study, we investigated whether the combination of simvastatin and ionizing radiation (IR) would enhance the antitumor effects of IR alone in HCT116 p53+/+ and p53‑/- colon cancer cells. Using colony formation assays and a xenograft mouse model, we found that simvastatin potently stimulated radiosensitization of HCT116 p53‑/- cells and xenograft tumors. The combination of simvastatin with IR decreased G2/M arrest and delayed the repair of IR-induced DNA damage; however, no differences between the HCT116 p53+/+ and p53‑/- cells were evident. A further analysis revealed that simvastatin exhibited a novel function, namely, MDM2 suppression, regardless of p53 status. Interestingly, simvastatin induced radiosensitization by enhancing MDM2 suppression and elevating IR-induced p‑ATM foci formation compared with IR alone in HCT116 p53‑/- cells. Furthermore, simvastatin caused accumulations of the FOXO3a, E-cadherin, and p21 tumor suppressor proteins, which are downstream factors of MDM2, in HCT116 p53‑/- cells. In conclusion, simvastatin enhanced radiosensitivity by inducing MDM2 inhibition and increasing tumor suppressor protein levels in radioresistant HCT116 p53‑/- cells and xenografts. Overall, our novel findings suggest a scientific rationale for the clinical use of simvastatin as an MDM2 inhibitor and radiosensitizer for p53‑deficient colorectal tumor treatments.

View Figures

View References

1	Novac N: Challenges and opportunities of drug repositioning. Trends Pharmacol Sci. 34:267–272. 2013. View Article : Google Scholar : PubMed/NCBI
2	Ashburn TT and Thor KB: Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 3:673–683. 2004. View Article : Google Scholar : PubMed/NCBI
3	Shen YY, Yuan Y, Du YY and Pan YY: Molecular mechanism underlying the anticancer effect of simvastatin on MDA-MB-231 human breast cancer cells. Mol Med Rep. 12:623–630. 2015. View Article : Google Scholar : PubMed/NCBI
4	Hoque A, Chen H and Xu XC: Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 17:88–94. 2008. View Article : Google Scholar : PubMed/NCBI
5	Hindler K, Cleeland CS, Rivera E and Collard CD: The role of statins in cancer therapy. Oncologist. 11:306–315. 2006. View Article : Google Scholar : PubMed/NCBI
6	Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, Cartenì M and Morelli F: Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol. 40:935–941. 2012. View Article : Google Scholar
7	Relja B, Meder F, Wilhelm K, Henrich D, Marzi I and Lehnert M: Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 26:735–741. 2010. View Article : Google Scholar : PubMed/NCBI
8	Huang X, Ma J, Xu J, Su Q and Zhao J: Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression. Mol Med Rep. 11:2334–2340. 2015. View Article : Google Scholar
9	Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, Guo X, Wang W, Jiao W, Xu Z, et al: Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS One. 8:e628232013. View Article : Google Scholar : PubMed/NCBI
10	Wang T, Seah S, Loh X, Chan CW, Hartman M, Goh BC and Lee SC: Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 7:2532–2544. 2016. View Article : Google Scholar :
11	Lim T, Lee I, Kim J and Kang WK: Synergistic effect of simvastatin plus radiation in gastric cancer and colorectal cancer: Implications of BIRC5 and connective tissue growth factor. Int J Radiat Oncol Biol Phys. 93:316–325. 2015. View Article : Google Scholar : PubMed/NCBI
12	Wang Y, Xu SL, Wu YZ, Zhao MS, Xu WJ, Yang HY and Li YX: Simvastatin induces caspase-dependent apoptosis and activates P53 in OCM-1 cells. Exp Eye Res. 113:128–134. 2013. View Article : Google Scholar : PubMed/NCBI
13	Koyuturk M, Ersoz M and Altiok N: Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett. 250:220–228. 2007. View Article : Google Scholar
14	Kumar S: Second malignant neoplasms following radiotherapy. Int J Environ Res Public Health. 9:4744–4759. 2012. View Article : Google Scholar : PubMed/NCBI
15	Klein HL: The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst). 7:686–693. 2008. View Article : Google Scholar
16	Rohwer N and Cramer T: Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 14:191–201. 2011. View Article : Google Scholar : PubMed/NCBI
17	El-Deiry WS: The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 22:7486–7495. 2003. View Article : Google Scholar : PubMed/NCBI
18	Böhnke A, Westphal F, Schmidt A, El-Awady RA and Dahm-Daphi J: Role of p53 mutations, protein function and DNA damage for the radiosensitivity of human tumour cells. Int J Radiat Biol. 80:53–63. 2004. View Article : Google Scholar : PubMed/NCBI
19	Gudkov AV and Komarova EA: The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 3:117–129. 2003. View Article : Google Scholar : PubMed/NCBI
20	Alarcon-Vargas D and Ronai Z: p53-Mdm2 - the affair that never ends. Carcinogenesis. 23:541–547. 2002. View Article : Google Scholar : PubMed/NCBI
21	Meek DW: Tumour suppression by p53: A role for the DNA damage response? Nat Rev Cancer. 9:714–723. 2009.PubMed/NCBI
22	Ganguli G and Wasylyk B: p53-independent functions of MDM2. Mol Cancer Res. 1:1027–1035. 2003.
23	Zhang Z and Zhang R: p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets. 5:9–20. 2005. View Article : Google Scholar : PubMed/NCBI
24	Rayburn E, Zhang R, He J and Wang H: MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets. 5:27–41. 2005. View Article : Google Scholar : PubMed/NCBI
25	Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S and Hamstra DA: MDM2 inhibition sensitizes prostate cancer cells to androgen ablation and radiotherapy in a p53-dependent manner. Neoplasia. 18:213–222. 2016. View Article : Google Scholar : PubMed/NCBI
26	Zhang Z, Wang H, Li M, Agrawal S, Chen X and Zhang R: MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem. 279:16000–16006. 2004. View Article : Google Scholar : PubMed/NCBI
27	Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S and Zhang R: Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res. 10:1263–1273. 2004. View Article : Google Scholar : PubMed/NCBI
28	Duong HQ, You KS, Oh S, Kwak SJ and Seong YS: Silencing of NRF2 reduces the expression of ALDH1A1 and ALDH3A1 and sensitizes to 5-FU in pancreatic cancer cells. Antioxidants. 6:62017. View Article : Google Scholar
29	Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest. 110:285–288. 2002. View Article : Google Scholar : PubMed/NCBI
30	Hwang KE, Na KS, Park DS, Choi KH, Kim BR, Shim H, Jeong ET and Kim HR: Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 29:945–952. 2011. View Article : Google Scholar
31	Shi D and Gu W: Dual roles of MDM2 in the regulation of p53: Ubiquitination dependent and ubiquitination independent mechanisms of MDM2 repression of p53 activity. Genes Cancer. 3:240–248. 2012. View Article : Google Scholar : PubMed/NCBI
32	Li Q and Lozano G: Molecular pathways: Targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res. 19:34–41. 2013. View Article : Google Scholar :
33	Chen L, Gilkes DM, Pan Y, Lane WS and Chen J: ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 24:3411–3422. 2005. View Article : Google Scholar : PubMed/NCBI
34	Perry ME: Mdm2 in the response to radiation. Mol Cancer Res. 2:9–19. 2004.PubMed/NCBI
35	de Toledo SM, Azzam EI, Dahlberg WK, Gooding TB and Little JB: ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation. Oncogene. 19:6185–6193. 2000. View Article : Google Scholar
36	Perry ME: The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harb Perspect Biol. 2:a0009682010. View Article : Google Scholar : PubMed/NCBI